Latest news
Innovent, Daiichi Sankyo Partner to Commercialise Vanflyta for FLT3-ITD Positive AML in China - BioPharma APACBioPharma APAC · Mon, 10 Aug 2026 18:33:43 GMTM&A Roundup: Novo Nordisk Enters AI Drug Discovery Partnership with Amazon, Innate Pharma Partners with Sobi, Innovent Enters Commercialization Agreement with Daiichi Sankyo - pharmexec.compharmexec.com · Mon, 10 Aug 2026 13:57:46 GMTInnovent Adds Vanflyta to China Oncology Portfolio - Contract PharmaContract Pharma · Mon, 10 Aug 2026 12:39:04 GMTInnoVent starts construction of 10-MW solar project in Eswatini - Renewables NowRenewables Now · Mon, 10 Aug 2026 12:26:20 GMTInnovent and Daiichi Sankyo sign deal for Vanflyta in China - Pharmaceutical TechnologyPharmaceutical Technology · Mon, 10 Aug 2026 09:48:32 GMTInnovent Announces First Patient Dosed in Pivotal Registrational Study of IBI363/TAK-928 (PD-1/IL-2a-biased Bispecific Fusion Protein) in Combination with Bevacizumab in Late-Line Advanced Colorectal Cancer in China - marketscreener.commarketscreener.com · Thu, 06 Aug 2026 02:05:27 GMTInnovent Announces First Patient Dosed in Pivotal Registrational Study of IBI363/TAK-928 (PD-1/IL-2α-biased Bispecific Fusion Protein) in Combination with Bevacizumab in Late-Line Advanced Colorectal Cancer in China - Banning Record GazetteBanning Record Gazette · Thu, 06 Aug 2026 00:00:00 GMTInnovent Biologics' Product Revenue Surges 60% in Q2 - MoomooMoomoo · Wed, 05 Aug 2026 03:08:06 GMT